FGFR3 – a Central Player in Bladder Cancer Pathogenesis?
Open Access
- 9 September 2020
- journal article
- review article
- Published by SAGE Publications in Bladder Cancer
- Vol. 6 (4) , 403-423
Abstract
The identification of mutations in FGFR3 in bladder tumors in 1999 led to major interest in this receptor and during the subsequent 20 years much has been learnt about the mutational profiles found in bladder cancer, the phenotypes associated with these and the potential of this mutated protein as a target for therapy. Based on mutational and expression data, it is estimated that >80% of non-muscle-invasive bladder cancers (NMIBC) and ∼40% of muscle-invasive bladder cancers (MIBC) have upregulated FGFR3 signalling, and these frequencies are likely to be even higher if alternative splicing of the receptor, expression of ligands and changes in regulatory mechanisms are taken into account. Major efforts by the pharmaceutical industry have led to development of a range of agents targeting FGFR3 and other FGF receptors. Several of these have entered clinical trials, and some have presented very encouraging early results in advanced bladder cancer. Recent reviews have summarised the drugs and related clinical trials in this area. This review will summarise what is known about the effects of FGFR3 and its mutant forms in normal urothelium and bladder tumors, will suggest when and how this protein contributes to urothelial cancer pathogenesis and will highlight areas that may benefit from further study.Keywords
This publication has 193 references indexed in Scilit:
- CDKN2A homozygous deletion is associated with muscle invasion in FGFR3 ‐mutated urothelial bladder carcinomaThe Journal of Pathology, 2012
- The FGFR3 Mutation is Related to Favorable pT1 Bladder CancerJournal of Urology, 2012
- ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cellsInternational Journal of Cancer, 2011
- Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer ProgressionThe American Journal of Pathology, 2011
- Overlapping functions of Pea3 ETS transcription factors in FGF signaling during zebrafish developmentDevelopmental Biology, 2010
- A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancerNature Genetics, 2010
- FGF-Regulated Etv Genes Are Essential for Repressing Shh Expression in Mouse Limb BudsDevelopmental Cell, 2009
- Fgf-Dependent Etv4/5 Activity Is Required for Posterior Restriction of Sonic hedgehog and Promoting Outgrowth of the Vertebrate LimbDevelopmental Cell, 2009
- FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK PathwayCancer Cell, 2007
- FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerThe Journal of Pathology, 2007